DK2897A - Fremgangsmåde til fremstilling af ikke-solvatiseret krystallinsk 6-hydroxy-2-(4-hydroxyphenyl)-3-(4-(2-piperidinoethoxy)benzoyl)benzo(b)thiophenhydrochlorid og krystallinske solvater af forbindelsen til brug ved fremgangsmåden - Google Patents

Fremgangsmåde til fremstilling af ikke-solvatiseret krystallinsk 6-hydroxy-2-(4-hydroxyphenyl)-3-(4-(2-piperidinoethoxy)benzoyl)benzo(b)thiophenhydrochlorid og krystallinske solvater af forbindelsen til brug ved fremgangsmåden Download PDF

Info

Publication number
DK2897A
DK2897A DK002897A DK2897A DK2897A DK 2897 A DK2897 A DK 2897A DK 002897 A DK002897 A DK 002897A DK 2897 A DK2897 A DK 2897A DK 2897 A DK2897 A DK 2897A
Authority
DK
Denmark
Prior art keywords
crystalline
piperidinoethoxy
benzo
hydroxyphenyl
benzoyl
Prior art date
Application number
DK002897A
Other languages
English (en)
Other versions
DK175886B1 (da
Inventor
Elizabeth Smith Labell
Wayne Douglas Luke
Iii John Mcneill Mcgill
Randal Scot Miller
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976194&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2897(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/308,325 external-priority patent/US5629425A/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DK2897A publication Critical patent/DK2897A/da
Application granted granted Critical
Publication of DK175886B1 publication Critical patent/DK175886B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK199700028A 1994-09-19 1997-01-09 Fremgangsmåde til fremstilling af ikke-solvatiseret krystallinsk 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophenhydrochlorid DK175886B1 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US08/308,325 US5629425A (en) 1994-09-19 1994-09-19 Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
US30832594 1994-09-19
US42791495A 1995-04-26 1995-04-26
US42791495 1995-04-26
DK199501028A DK175897B1 (da) 1994-09-19 1995-09-15 Fremgangsmåde til fremstilling af ikke-solvatiseret krystallinsk 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(piperidinoethoxy)benzoyl]benzo[b]thiophenhydrochlorid og krystallinske solvater heraf til brug ved fremgangsmåden
DK102895 1995-09-15

Publications (2)

Publication Number Publication Date
DK2897A true DK2897A (da) 1997-01-09
DK175886B1 DK175886B1 (da) 2005-05-23

Family

ID=26976194

Family Applications (4)

Application Number Title Priority Date Filing Date
DK199501027A DK175903B1 (da) 1994-09-19 1995-09-15 Ikke-solvatiseret krystallinsk form af 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(piperidinoethoxy)benzoyl]benzo[b]thiophenhydrochlorid
DK199501028A DK175897B1 (da) 1994-09-19 1995-09-15 Fremgangsmåde til fremstilling af ikke-solvatiseret krystallinsk 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(piperidinoethoxy)benzoyl]benzo[b]thiophenhydrochlorid og krystallinske solvater heraf til brug ved fremgangsmåden
DK199700028A DK175886B1 (da) 1994-09-19 1997-01-09 Fremgangsmåde til fremstilling af ikke-solvatiseret krystallinsk 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophenhydrochlorid
DK199700027A DK175887B1 (da) 1994-09-19 1997-01-09 Fremgangsmåde til fremstilling af krystallinske solvater af 3-[4-(2-aminoethoxy)-benzoyl]-2-aryl-6-hydroxybenzo(b)thiophener

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK199501027A DK175903B1 (da) 1994-09-19 1995-09-15 Ikke-solvatiseret krystallinsk form af 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(piperidinoethoxy)benzoyl]benzo[b]thiophenhydrochlorid
DK199501028A DK175897B1 (da) 1994-09-19 1995-09-15 Fremgangsmåde til fremstilling af ikke-solvatiseret krystallinsk 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(piperidinoethoxy)benzoyl]benzo[b]thiophenhydrochlorid og krystallinske solvater heraf til brug ved fremgangsmåden

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK199700027A DK175887B1 (da) 1994-09-19 1997-01-09 Fremgangsmåde til fremstilling af krystallinske solvater af 3-[4-(2-aminoethoxy)-benzoyl]-2-aryl-6-hydroxybenzo(b)thiophener

Country Status (50)

Country Link
US (4) US6472531B1 (da)
JP (2) JP2860071B2 (da)
KR (2) KR100381346B1 (da)
CN (2) CN1068324C (da)
AP (1) AP754A (da)
AT (2) AT407988B (da)
AU (3) AU691955B2 (da)
BE (2) BE1009626A3 (da)
BG (1) BG62793B1 (da)
BR (2) BR9504060A (da)
CA (2) CA2158399C (da)
CH (3) CH691478A5 (da)
CO (2) CO4410190A1 (da)
CZ (2) CZ290343B6 (da)
DE (3) DE19534745B4 (da)
DK (4) DK175903B1 (da)
EE (1) EE03386B1 (da)
EG (1) EG23763A (da)
ES (2) ES2109882B1 (da)
FI (2) FI121424B (da)
FR (2) FR2732020B1 (da)
GB (2) GB2293602B (da)
GE (1) GEP19991821B (da)
GR (2) GR1002697B (da)
HR (2) HRP950482B1 (da)
HU (2) HU227683B1 (da)
IE (2) IE950722A1 (da)
IL (3) IL115315A (da)
IS (1) IS1788B (da)
IT (2) IT1277602B1 (da)
LU (2) LU88661A1 (da)
LV (2) LV11177B (da)
MY (1) MY116371A (da)
NL (2) NL1001196C2 (da)
NO (2) NO308107B1 (da)
NZ (2) NZ280028A (da)
OA (1) OA10406A (da)
PE (2) PE14796A1 (da)
PL (2) PL187686B1 (da)
PT (2) PT101771B (da)
RO (2) RO115260B1 (da)
RS (2) RS49578B (da)
SE (2) SE509265C2 (da)
SI (2) SI9500292A (da)
SK (1) SK283502B6 (da)
TR (1) TR199501136A2 (da)
TW (1) TW412534B (da)
UA (2) UA42716C2 (da)
UY (1) UY24040A1 (da)
WO (1) WO1996009045A1 (da)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
CO4410190A1 (es) * 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
DE69739855D1 (de) * 1996-03-26 2010-06-02 Lilly Co Eli Benzothiophene und denen enthaltende zusammensetzungen
US6458811B1 (en) * 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
ZA992858B (en) 1996-10-30 1999-07-29 Lilly Co Eli Methods of preventing breast cancer.
CA2236254A1 (en) * 1997-04-30 1998-10-30 David Warren Hoard Process for preparing benzo¬b|thiophenes
IL146284A0 (en) 1999-05-04 2002-07-25 Strakan Ltd Androgen glycosides and pharmaceutical compositions containing the same
AU2002230409A1 (en) * 2000-11-27 2002-06-03 Eli Lilly And Company Process for preparing 3-aryl-benzo(b)thiophenes
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
ATE541840T1 (de) 2002-09-30 2012-02-15 Gea Farmaceutisk Fabrik As Raloxifene-l-lactat oder ein hemihydrat davon, deren verwendungen, pharmazeutischen zusammensetzungen und herstellungsverfahren
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
KR101381454B1 (ko) 2004-09-29 2014-04-04 바이엘 인텔렉쳐 프로퍼티 게엠베하 열역학적으로 안정한 형태의 ｂａｙ 43-9006 토실레이트
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
WO2008047105A1 (en) * 2006-10-17 2008-04-24 Cipla Limited Crystalline form of benzothiophene compound and process for preparation thereof
US20080103295A1 (en) * 2006-10-25 2008-05-01 David Losan Ho Process for the preparation of sucrose-6-ester by esterification in the presence of solid superacid catalyst
US8258291B2 (en) * 2006-10-25 2012-09-04 Mamtek International Limited Process for the preparation of sucralose by the chlorination of sugar with triphosgene (BTC)
DE102007032451B4 (de) 2007-07-12 2010-09-30 Icfs Gmbh Verfahren zur Herstellung von aromatischen Ketonen
WO2009015004A1 (en) * 2007-07-20 2009-01-29 King Pharmaceuticals Research And Development, Inc. Crystals of (2-amino-4,5,6,7-tetrahydrobenzo[b]thien-3-yl)(4-chlorophenyl)methanone
EP2185559A1 (en) 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
EP2242483B1 (en) * 2007-12-21 2013-02-20 Synthon B.V. Raloxifene composition
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
EP2307399B1 (en) * 2008-06-09 2016-05-18 ERREGIERRE S.p.A. Process for controlling the growth of a raloxifene hydrochloride crystal
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN107011345A (zh) 2008-12-23 2017-08-04 勃林格殷格翰国际有限公司 有机化合物的盐形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
ES2437916T3 (es) 2009-07-02 2014-01-15 Synthon B.V. Composición de raloxifeno
EP2314581B1 (en) 2009-10-23 2012-07-25 Hexal AG A process for preparing benzo[b]thiophene derivatives
EP2504002B1 (en) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
KR20200028498A (ko) 2010-06-24 2020-03-16 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
IT1403083B1 (it) * 2010-10-25 2013-10-04 Fidia Farmaceutici Nuova forma polimorfa di raloxifene cloridrato
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
HUE061596T2 (hu) 2011-07-15 2023-07-28 Boehringer Ingelheim Int Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ZA201401636B (en) 2013-03-05 2014-11-26 Cipla Ltd Oxalic acid addition salts and/or solvates of a selective estrogen receptor modulator
WO2015011236A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CN104496963A (zh) * 2014-12-02 2015-04-08 千辉药业（安徽）有限责任公司 一种盐酸雷洛昔芬的制备方法
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina
KR102815172B1 (ko) * 2020-02-25 2025-05-29 엘지전자 주식회사 히트펌프 및 그 동작방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3869485A (en) * 1969-09-25 1975-03-04 Allied Chem Preparation of acid chlorides with phosgene in the presence of a catalyst
GB1456323A (en) * 1974-06-06 1976-11-24 Labaz Benzothiophenes process for preparing them and pharmaceutical compositions containing the same
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
NZ200204A (en) * 1981-04-03 1985-05-31 Lilly Co Eli Benzothiophene derivatives and process for preparation
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4358593A (en) 1981-04-03 1982-11-09 Eli Lilly And Company Process for preparing 3-(4-aminoethoxybenzoyl)benzo[b]thiophenes
IL65379A0 (en) * 1981-04-03 1982-05-31 Lilly Co Eli Process for preparing acylated benzothiophenes
IL65378A (en) 1981-04-03 1986-02-28 Lilly Co Eli Process for preparing 3-(4-aminoethoxybenzoyl)benzo-(b)thiophenes
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
ZA822247B (en) 1981-04-03 1983-11-30 Lilly Co Eli Benzothiophene compounds and process for preparing them
DE4117512A1 (de) * 1991-05-25 1992-11-26 Schering Ag 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5169860A (en) 1992-03-13 1992-12-08 Eli Lilly And Company Antitumor compositions and methods of treatment
TW383306B (en) 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
CZ285522B6 (cs) 1993-06-24 1999-08-11 Eli Lilly And Company Farmaceutický prostředek pro snížení koncentrace glukosy v krvi
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5523416A (en) 1994-07-22 1996-06-04 Eli Lilly And Company Process for preparing 3-(4-aminoethoxy-benzoyl) benzo (B)-thiophenes
CO4410190A1 (es) * 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO

Also Published As

Publication number Publication date
GR1002697B (el) 1997-05-22
KR100381346B1 (ko) 2004-04-13
AU3718695A (en) 1996-04-09
CA2158399C (en) 2001-03-20
YU61495A (sh) 1998-05-15
ES2109882A1 (es) 1998-01-16
CN1132205A (zh) 1996-10-02
CH691594A5 (de) 2001-08-31
NL1001196C2 (nl) 1997-04-04
HU225417B1 (en) 2006-11-28
FI121424B (fi) 2010-11-15
NZ280028A (en) 1997-05-26
IT1277602B1 (it) 1997-11-11
HU9502723D0 (en) 1995-11-28
GEP19991821B (en) 1999-11-05
HUT74178A (en) 1996-11-28
PT101771A (pt) 1996-04-30
PL310518A1 (en) 1996-04-01
PE32796A1 (es) 1996-08-07
IL115314A0 (en) 1996-05-14
US6472531B1 (en) 2002-10-29
HK1019009A1 (en) 2000-01-14
CH691478A5 (de) 2001-07-31
EG23763A (en) 2007-08-08
DE19549755B4 (de) 2005-05-04
ATA154295A (de) 2000-12-15
FR2724655B1 (fr) 1997-11-14
ITMI951935A1 (it) 1997-03-15
CN1075069C (zh) 2001-11-21
OA10406A (en) 2001-12-05
IE950722A1 (en) 1996-03-20
CZ290343B6 (cs) 2002-07-17
ES2109882B1 (es) 1998-08-16
PL182450B1 (pl) 2002-01-31
SE9503214L (sv) 1996-03-20
ITMI951936A1 (it) 1997-03-15
NL1001194C2 (nl) 1997-04-04
SE9503214D0 (sv) 1995-09-15
EE03386B1 (et) 2001-04-16
FI954403A0 (fi) 1995-09-18
DK175887B1 (da) 2005-05-23
SI9500292A (en) 1996-06-30
NO308107B1 (no) 2000-07-24
PT101770A (pt) 1996-04-30
NZ280027A (en) 1997-05-26
SK283502B6 (sk) 2003-08-05
AU691955B2 (en) 1998-05-28
IE80883B1 (en) 1999-05-19
RO115259B1 (ro) 1999-12-30
NO953658L (no) 1996-03-20
GB9519028D0 (en) 1995-11-15
KR100367376B1 (ko) 2003-03-06
RO115260B1 (ro) 1999-12-30
IL115314A (en) 2000-02-29
BE1009625A3 (fr) 1997-06-03
EE9700055A (et) 1997-08-15
ITMI951935A0 (it) 1995-09-15
NO313996B1 (no) 2003-01-13
LV11177A (lv) 1996-04-20
CZ240295A3 (en) 1996-04-17
CZ240395A3 (en) 1996-04-17
TR199501136A2 (tr) 1996-06-21
HU9502721D0 (en) 1995-11-28
FI954403A7 (fi) 1996-03-20
GB2293382A (en) 1996-03-27
FR2732020B1 (fr) 1997-11-14
CZ292007B6 (cs) 2003-07-16
PE14796A1 (es) 1996-05-19
US5731327A (en) 1998-03-24
LV11177B (en) 1996-08-20
AP9700938A0 (en) 1997-04-30
FR2724655A1 (fr) 1996-03-22
RS49513B (sr) 2006-10-27
LU88660A1 (fr) 1996-07-15
AU692907B2 (en) 1998-06-18
PT101770B (pt) 1997-04-30
AT407988B (de) 2001-07-25
SE509265C2 (sv) 1998-12-21
NO953657L (no) 1996-03-20
CA2158400C (en) 2006-10-24
UY24040A1 (es) 1996-03-07
HU227683B1 (en) 2011-11-28
UA44240C2 (uk) 2002-02-15
IL115315A0 (en) 1995-12-31
AU3173095A (en) 1996-04-04
DE19534745B4 (de) 2004-06-09
NL1001194A1 (nl) 1996-03-19
TW412534B (en) 2000-11-21
IL115315A (en) 1999-09-22
GB9519032D0 (en) 1995-11-15
LV11178A (lv) 1996-04-20
DK102895A (da) 1996-03-20
DE19534745A1 (de) 1996-04-04
CA2158400A1 (en) 1996-03-20
AP754A (en) 1999-07-22
IS1788B (is) 2001-11-28
IS4446A (is) 1997-03-18
HRP950483A2 (en) 1997-10-31
ITMI951936A0 (it) 1995-09-15
DE19534744A1 (de) 1996-03-21
PT101771B (pt) 1997-04-30
BR9504059A (pt) 1996-09-24
KR960010634A (ko) 1996-04-20
FR2732020A1 (fr) 1996-09-27
GB2293602B (en) 1998-05-06
CN1068324C (zh) 2001-07-11
SE9503213L (sv) 1996-03-20
HRP950483B1 (en) 2003-02-28
NO953658D0 (no) 1995-09-15
CO4410191A1 (es) 1997-01-09
GB2293382B (en) 1998-08-19
JPH08193081A (ja) 1996-07-30
DK175903B1 (da) 2005-06-06
NO953657D0 (no) 1995-09-15
SI9500293A (en) 1996-06-30
JPH08176147A (ja) 1996-07-09
ES2129293A1 (es) 1999-06-01
IL125283A (en) 2001-06-14
US6399778B1 (en) 2002-06-04
CO4410190A1 (es) 1997-01-09
YU61395A (sh) 1998-09-18
CH691125A5 (de) 2001-04-30
HRP950482B1 (en) 2007-04-30
PL310517A1 (en) 1996-04-01
FI112226B (fi) 2003-11-14
DK102795A (da) 1996-03-20
IT1277601B1 (it) 1997-11-11
JP2860071B2 (ja) 1999-02-24
SE520721C2 (sv) 2003-08-12
BG62793B1 (bg) 2000-08-31
LV11178B (en) 1996-08-20
BE1009626A3 (fr) 1997-06-03
DK175897B1 (da) 2005-05-30
HUT75033A (en) 1997-03-28
CN1127253A (zh) 1996-07-24
DK175886B1 (da) 2005-05-23
GB2293602A (en) 1996-04-03
HRP950482A2 (en) 1998-02-28
GR1002709B (el) 1997-06-04
NL1001196A1 (nl) 1996-03-19
AT502957A1 (de) 2007-06-15
WO1996009045A1 (en) 1996-03-28
AU3173195A (en) 1996-04-04
UA42716C2 (uk) 2001-11-15
PL187686B1 (pl) 2004-09-30
FI954402A0 (fi) 1995-09-18
MY116371A (en) 2004-01-31
ES2129293B1 (es) 2000-01-16
SK23397A3 (en) 1997-08-06
FI954402L (fi) 1996-03-20
US20020173645A1 (en) 2002-11-21
BR9504060A (pt) 1996-09-24
BG101242A (en) 1998-03-31
CA2158399A1 (en) 1996-03-20
SE9503213D0 (sv) 1995-09-15
LU88661A1 (fr) 1996-07-15
IE950721A1 (en) 1996-03-20
DK2797A (da) 1997-01-09
KR960010637A (ko) 1996-04-20
RS49578B (sr) 2007-04-10

Similar Documents

Publication Publication Date Title
DK2897A (da) Fremgangsmåde til fremstilling af ikke-solvatiseret krystallinsk 6-hydroxy-2-(4-hydroxyphenyl)-3-(4-(2-piperidinoethoxy)benzoyl)benzo(b)thiophenhydrochlorid og krystallinske solvater af forbindelsen til brug ved fremgangsmåden
NO933093D0 (no) Monohydrat av 5-(2-(4-(1,2-benzisotiazol-3-yl)-1-piperazinyl)-etyl)-6-klor-1,3-dihydro-2h-indol-2-on hydroklorid
MY112481A (en) Synthesis of 3-[4-(2-aminoethoxy)-benzoyl] -2-aryl-6-hydroxybenzo [b] thiophenes
SG44989A1 (en) Crystalline hydrochloride of (R)-(-)-2-{N-[4-(1,1-dioxid-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl}-chroman
NZ270164A (en) Use of 3-[4-(pyrrolidino or -piperidinoethoxy)phenylcarbonyl]-2-(4-hydroxyphenyl)benzothiophene derivatives (such as raloxifene) for the preparation of medicaments for inhibiting autoimmune diseases
LU90616B1 (fr) Nouvelle forme cristalline du chlorhydrate de 6-hydroxy-3-(4-(2-(piperidin-1-YL)ethoxy)phenoxy)-2-(4-methoxyphenyl)benzo(b)thiophene
SG91296A1 (en) A novel crystalline form of 6-hydroxy-3-[4-[2-(piperidin-1-yl) ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo [b] thiophene hydrochloride
HUP0301403A3 (en) A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride and it's use
EP0794956A4 (en) Substituted 2-(phosphinyloxymethyl)-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof
EP0792150A4 (en) 1,1-DIOXIDES OF 2- (2,3,5,6-TETRAFLUORO-4-PYRIDYL) -1,2,5-THIADIAZOLIDIN-3-ONE, COMPOSITIONS AND METHOD OF USE
CY2344B1 (en) A novel crystalline form of 6-hydroxy-3-(4-(2-(piperidin-1-yl) ethoxy) phenoxy)-2-(4-methoxyphenyl) benzo (b) thiphene hydrochloride.
FI925951A7 (fi) N-(3-(2-(1H-imidatsol-1-yyli)etoksi)fenyyli)-4-(2-tienyyli)-2-pyrimidiiniamiini ja farmakologisesti hyväksyttävät suolat
EP0699675A3 (en) 3- (4- (1-Substituted-4-piperazinyl) butyl) -4-thiazolidinone and related compounds

Legal Events

Date Code Title Description
PBP Patent lapsed

Effective date: 20140930